COMMUNIQUÉS West-GlobeNewswire

WHO endorses dual-stain cytology (CINtec PLUS) testing in its cervical cancer prevention guidelines, advancing patient care and underlining Roche’s role in pioneering cervical cancer solutions

23/09/2024 - 07:00

Roche’s CINtec PLUS Cytology is the only FDA-approved and CE-marked dual-stain test to triage human papillomavirus (HPV)-positive cervical cancer screening test results Dual-stain biomarkers aid in detection of cervical [...]

Telix to Acquire RLS to Expand North American Manufacturing and Distribution Platform

23/09/2024 - 00:59

MELBOURNE, Australia and INDIANAPOLIS, Ind. and LAKE MARY, Fla., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) and RLS (USA) Inc. (RLS, RLS Radiopharmacies), America’s [...]

Black Diamond Therapeutics to Host Webcast Presentation of Initial Phase 2 BDTX-1535 Data in Patients With Recurrent EGFRm NSCLC

22/09/2024 - 16:00

Webcast to be held Monday, September 23, at 8:00 a.m. ET CAMBRIDGE, Mass., Sept. 22, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey [...]

Teva Presents New Phase 3 Efficacy, Safety and Tolerability Data from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable for Adult Patients Diagnosed with Schizophrenia

21/09/2024 - 10:15

As a leader in neuroscience, Teva is committed to researching new treatment innovations that may help address unmet needs in treating schizophrenia , including TEV -‘ 749 Currently, there is no long-acting olanzapine [...]

New Data Provide Treatment Insights into Options for Switching Adult Patients Diagnosed with Schizophrenia to UZEDY® (risperidone) Extended-Release Injectable Suspension from Perseris® (RBP-7000)

21/09/2024 - 10:10

As a leader in neuroscience, Teva remains committed to helping address unmet needs in the treatment of schizophrenia throu gh scientific and clinical advances that support optimal treatment options and decisions for [...]

Press Release: Sarclisa approved in the US as the first anti-CD38 therapy in combination with standard-of-care treatment for adult patients with newly diagnosed multiple myeloma not eligible for transplant

21/09/2024 - 00:36

Sarclisa approved in the US as the first anti-CD38 therapy in combination with standard-of-care treatment for adult patients with newly diagnosed multiple myeloma not eligible for transplant Approval based on positive [...]

Communiqué de presse : Approbation du Sarclisa aux États-Unis : premier anti-CD38, en association avec un traitement conventionnel, pour les patients atteints d’un myélome multiple nouvellement diagnostiqué (...)

21/09/2024 - 00:36

Approbation du Sarclisa aux États-Unis : premier anti-CD38, en association avec un traitement conventionnel, pour les patients atteints d’un myélome multiple nouvellement diagnostiqué, non éligibles à une [...]

Smart for Life Provides Update Following Nasdaq Delisting Due to Audit Delays; Reports Plans to Reapply to Nasdaq Upon Full Compliance

20/09/2024 - 22:40

MIAMI, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Smart for Life, Inc. (OTC: SMFL) (“Smart for Life” or the “Company”), a distinguished leader in the Health & Wellness sector specializing in the marketing and manufacturing [...]

Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

20/09/2024 - 22:30

BRISBANE, Calif., Sept. 20, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class 1 targeted and immune-mediated therapeutics to fight [...]

Universe Pharmaceuticals INC Reports Financial Results for The First Six Months of Fiscal Year 2024

20/09/2024 - 22:15

JI’AN, Jiangxi, China, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Universe Pharmaceuticals INC (the “Company,” “we,” “our” and “us”) (Nasdaq: UPC), a pharmaceutical producer and distributor in China, today announced its [...]

Sutro Biopharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

20/09/2024 - 22:01

SOUTH SAN FRANCISCO, Calif., Sept. 20, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody-drug [...]

ONWARD® Medical Annonce la Cotation de ses Titres sur le Marché Euronext Paris

20/09/2024 - 19:45

La société a des racines françaises et des liens significatifs avec la France La société collabore étroitement avec le CEA-Clinatec, institut de recherche biomédicale de renommée mondiale financé par le gouvernement [...]

L’Arche Vancouver opens new $37-Million Dream Home

20/09/2024 - 18:59

BURNABY, British Columbia, Sept. 20, 2024 (GLOBE NEWSWIRE) -- L’Arche Greater Vancouver has fulfilled the biggest dream in its 50-year history today, by replacing its old building on the Sussex Avenue property in [...]

Wounded Warriors Family Support Provides Veterans with Program Toward Financial Competency, Independence

20/09/2024 - 18:48

OMAHA, Neb., Sept. 20, 2024 (GLOBE NEWSWIRE) -- According to a 2021 Military Family Support Programming Survey, 80.7% of respondents indicated that their finances caused them some stress over the past 12 months. The [...]

Zevra Therapeutics’ MIPLYFFA™ (arimoclomol) Receives U.S. FDA Approval as Treatment for Niemann-Pick Disease Type C

20/09/2024 - 18:08

MIPLYFFA is the first FDA-approved treatment for Niemann-Pick disease type C (NPC), an ultra-rare and progressive neurodegenerative disease MIPLYFFA is indicated for use in combination with miglustat for the treatment [...]

TRxADE Health, Inc. Announces Name Change to Scienture Holdings, Inc.

20/09/2024 - 17:59

TAMPA, FL and COMMACK, NY, Sept. 20, 2024 (GLOBE NEWSWIRE) -- TRxADE Health, Inc. (“TRxADE”) (NASDAQ: MEDS) and Scienture, LLC (“Scienture”), a wholly owned subsidiary of TRxADE, today announced that it is changing its [...]

Onconetix, Inc. Announces 1-for-40 Reverse Stock Split and Results of the Annual Meeting of Stockholders

20/09/2024 - 17:45

CINCINNATI, Ohio, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ: ONCO) (“Onconetix” or the “Company”), a commercial-stage biotechnology company focused on the research, development, and commercialization of [...]

Psyence Group Enters into Agreement to Dispose of Stake in PsyLabs

20/09/2024 - 17:20

PsyLabs develops and produces certified pharmaceutical-grade natural psychedelics for applications in mental health and well-being NEW YORK, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Psyence Group Inc (" Psyence Group " or the [...]

ChemoMetec makes offer to buy Ovizio Imaging Systems SA

20/09/2024 - 17:06

ANNOUNCEMENT NO. 276 20 September 2024 ChemoMetec makes offer to buy Ovizio Imaging Systems SA ChemoMetec has submitted an indicative offer to buy Belgian company Ovizio Imaging Systems (‘Ovizio’), which has been [...]